ABCL - 568
Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin (Mosun-Pola) Shows a Sustained Progression-Free Survival Benefit Compared With Rituximab Plus Polatuzumab Vedotin (R-Pola) in Patients With Relapsed or Refractory Large B-Cell Lymphoma After Long-Term Follow-Up
L Elizabeth Budde
Poster Presenter: L Elizabeth Budde